Living Fully: Joanne’s Cancer Journey
Living Fully with Non-Small Cell Lung Cancer: Joanne’s Story of Hope and Healing
When Joanne was diagnosed with non-small cell lung cancer in 2021, she couldn’t help but ask the same question many patients face: “Why me?” She had lived a healthy lifestyle, exercised, and avoided processed foods, yet found herself retracing her past for answers—secondhand smoke in childhood, brief years of social smoking, exposure to environmental toxins, stress, or perhaps random chance. Her pathology revealed an EGFR mutation, a genetic change often seen in people with little or no smoking history, which allowed her to begin targeted therapy after surgery and chemotherapy.
Over time, Joanne realized that focusing on blame only robs her of peace. Instead, she has chosen to center her life around gratitude, faith, and the love of her husband and community. With new advances in treatment, she believes lung cancer should no longer be viewed as an automatic death sentence or a punishment tied to smoking. Through sharing her story, Joanne hopes to break the stigma, reminding us that compassion and understanding—not judgment—are what every patient deserves. (Source: Joanne Gaget Blog)
Targeted Pill Delays Lung Cancer Return
A new treatment is bringing hope to people with stage 3 non-small cell lung cancer (NSCLC) that has a mutation in a gene called EGFR, which stands for epidermal growth factor receptor. This gene helps cells grow, and when it’s mutated, it can cause cancer to grow faster. These EGFR mutations are found in many people with lung cancer—especially never smokers and those of Asian descent.
In the LAURA trial, patients who had already completed chemotherapy and radiation were given the pill Tagrisso (osimertinib) to help prevent their cancer from coming back. The study, led by Dr. Suresh Ramalingam of Winship Cancer Institute at Emory University, showed powerful results: people who took Tagrisso stayed cancer-free for a median of 39 months—compared to just 5.6 months in the group that didn’t take the drug. That means Tagrisso reduced the risk of cancer returning or spreading by 84%.
While some patients experienced side effects like inflammation in the lungs, no new safety issues were found. Tagrisso is now the first targeted therapy to show such a strong benefit for stage 3 EGFR-positive lung cancer. Doctors believe this could become the new standard of care—offering more time and hope to patients with this aggressive form of lung cancer. (Source: Winship Cancer Institute at Emory University)
